A potential diagnostic marker for ovarian cancer: Involvement of the histone acetyltransferase, human males absent on the first

Liu,Ning; Zhang,Rui; Zhao,Xiaoming; Su,Jiaming; Bian,Xiaolei; Ni,Jinsong; Yue,Ying; Cai,Yong; Jin,Jingji

doi:10.3892/ol.2013.1380

A potential diagnostic marker for ovarian cancer: Involvement of the histone acetyltransferase, human males absent on the first

Authors:
- Ning Liu
- Rui Zhang
- Xiaoming Zhao
- Jiaming Su
- Xiaolei Bian
- Jinsong Ni
- Ying Yue
- Yong Cai
- Jingji Jin
View Affiliations

Affiliations: Department of Gynecological Oncology, The First Clinical Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, College of Life Science, Jilin University, Changchun, Jilin 130012, P.R. China, Department of Pathology, The First Clinical Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: June 7, 2013 https://doi.org/10.3892/ol.2013.1380
Pages: 393-400

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human males absent on the first (hMOF), a human ortholog of the Drosophila MOF protein, is responsible for histone H4 lysine 16 (H4K16) acetylation in human cells. The depletion of hMOF leads to a global reduction in histone H4K16 acetylation in human cells, genomic instability, cell cycle defects, reduced transcription of certain genes, defective DNA damage repair and early embryonic lethality. Studies have shown that abnormal hMOF gene expression is involved in a number of primary cancers. The present study examined the involvement of hMOF expression and histone H4K16 acetylation in clinically diagnosed primary ovarian cancer tissues. Clinically diagnosed frozen primary ovarian cancer tissues were used for polymerase chain reaction (PCR), quantitative PCR (qPCR), western blotting and immunohistochemical staining approaches. A PCR analysis of mRNA expression in 47 samples revealed a downregulation of hMOF mRNA in 81% of patients, whereas only 13% of patients demonstrated upregulation. qPCR was used to validate the frequent downregulation of hMOF expression in the primary ovarian cancer tissues. As expected, the analysis of hMOF expression in 57 samples revealed that hMOF mRNA expression was significantly downregulated (>2‑fold decrease) in 65% of patients, while a <2‑fold reduction of hMOF was observed in 10.5% of patients. Furthermore, the expression of hMOF‑regulated human leukocyte antigen (HLA) complex 5, (HCP5), was also found to be downregulated in >87% of patients with a decrease in hMOF. hMOF and its regulated gene, HCP5, are frequently downregulated in human ovarian cancer, suggesting that hMOF may be involved in the pathogenesis of the disease.

View Figures

View References

1.	Hilfiker A, Hilfiker-Kleiner D, Pannuti A and Lucchesi JC: mof, a putative acetyl transferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila. EMBO J. 16:2054–2060. 1997. View Article : Google Scholar : PubMed/NCBI
2.	Smith ER, Cayrou C, Huang R, Lane WS, Côtê J and Lucchesi JC: A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol. 25:9175–9188. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Mendjan S, Taipale M, Kind J, Holz H, Gebhardt P, Schelder M, Vermeulen M, Buscaino A, Duncan K, Mueller J, Wilm M, Stunnenberg HG, Saumweber H and Akhtar A: Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol Cell. 21:811–823. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Cai Y, Jin J, Swanson SK, Cole MD, Choi SH, Florens L, Washburn MP, Conaway JW and Conaway RC: Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. J Biol Chem. 285:4268–4272. 2010. View Article : Google Scholar
5.	Carrozza MJ, Utley RT, Workman JL and Côté J: The diverse functions of histone acetyltransferase complexes. Trends Genet. 19:321–329. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Gupta A, Guerin-Peyrou TG, Sharma GG, Park C, Agarwal M, Ganju RK, Pandita S, Choi K, Sukumar S, Pandita RK, Ludwig T and Pandita TK: The mammalian ortholog of Drosophla MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol. 28:397–409. 2008.
7.	Sharma GG, So S, Gupta A, Kumar R, Cayrou C, Avvakumov N, Bhadra U, Pandita RK, Porteus MH, Chen DJ, Cote J and Pandita TK: MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol. 30:3582–3595. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Rea S, Xouri G and Akhtar A: Males absent on the first (MOF): from flies to humans. Oncogene. 26:5385–5394. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Taipale M, Rea S, Richter K, Vilar A, Lichter P, Imhof A and Akhtar A: hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol. 25:6798–6810. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
11.	Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smish KD, Cushing RC and Seagroves TN: Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res. 14:R62012.
12.	McDonald PC, Winum JY, Supuran CT and Dedhar S: Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 3:84–97. 2012.PubMed/NCBI
13.	Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res. 316:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Choschzick M, Oosterwijk E, Müller V, Woelber L, Simon R, Moch H and Tennstedt P: Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch. 459:193–200. 2011. View Article : Google Scholar : PubMed/NCBI
15.	Seeber LM, Horrée N, Vooijs MA, Heintz AP, van der Wall E, Verheijen RH and van Diest PJ: The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol. 78:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM and Ellis IO: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 69:3802–3809. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Pfister S, Rea S, Taipale M, Mendrzyk F, Straub B, Ittrich C, Thuerigen O, Sinn HP, Akhtar A and Lichter P: The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 122:1207–1213. 2008. View Article : Google Scholar
18.	Kulski JK and Dawkins RL: The P5 multicopy gene family in the MHC is related in sequence to human endogenous retroviruses HERV-L and HERV-16. Immunogenetics. 49:404–412. 1999. View Article : Google Scholar : PubMed/NCBI
19.	Salih HR and Nüssler V: Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res. 6:323–332. 2001.PubMed/NCBI
20.	Kübler K, Arndt PF, Wardelmann E, Landwehr C, Krebs D, Kuhn W and van der Ven K: Genetic alterations of HLA-class II in ovarian cancer. Int J Cancer. 123:1350–1356. 2008.PubMed/NCBI
21.	Wang Y, Zhang R, Wu D, Lu Z, Sun W, Cai Y, Wang C and Jin J: Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma. J Exp Clin Cancer Res. 32:82013. View Article : Google Scholar : PubMed/NCBI
22.	Seeber LM and van Diest PJ: Epigenetics in ovarian cancer. Methods Mol Biol. 863:253–269. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Asadollahi R, Hyde CA and Zhong XY: Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol Oncol. 118:81–87. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Balch C, Matei DE, Huang TH and Nephew KP: Role of epigenomics in ovarian and endometrial cancers. Epigenomics. 2:419–447. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Song JS, Chun SM, Lee JY, Kim DK, Kim YH and Jang SJ: The histone acetyltransferase hMOF is overexpressed in non-small cell lung carcinoma. Korean J Pathol. 45:386–396. 2011. View Article : Google Scholar